Biologics in current therapy for inflammatory bowel disease

Volume: 32, Issue: 3, Pages: 168 - 179
Published: Jun 1, 2009
Abstract
Recent advance of molecular biology and immunology contributes to the development biologics such as anti-TNFalpha agent in the treatment for inflammatory bowel disease (IBD). Although therapeutic strategy of IBD has not been changed for a long time, success of Infliximab, first anti-TNFalpha agent, now changes therapeutic strategy of IBD dramatically. Top-down strategy has been considered to improve patients' natural history in the therapy for...
Paper Details
Title
Biologics in current therapy for inflammatory bowel disease
Published Date
Jun 1, 2009
Volume
32
Issue
3
Pages
168 - 179
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.